CD44 and breast cancer: Al-Hajj's research in 2003 has shown that breast cancer stem cells (ESA+CD44+CD24-/low, BCSCs) possessing the stem cell properties of self-renewal and multi-directional differentiation are the most fundamental contributors to drug resistance, recurrence and metastasis of breast cancer [1].